Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Official title: A Randomized Controlled Trial to Assess the Efficacy and Safety of Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Status: Recruiting now
Description:
This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment. Patients with stable NSV at least 0.5% of their total body surface area (BSA) on the face and neck, as determined by the fingertip method, are screened. Recruited subjects will be asked to review their impression of change of their lesion by the end of the study using a 7-point scale.
Phases: Phase 2, Phase 3.
What is being studied: drugs — Ruxolitinib Cream 1.5%, Aqueous cream.
Who can take part: ages 18 Years to 85 Years, 20 participants planned.
Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 29 November 2024 and was due to finish 30 January 2026.
Contact: Research Assistant.
Source: ClinicalTrials.gov, NCT06719024 (https://clinicaltrials.gov/study/NCT06719024).
Start date: November 29, 2024
Completion date: January 30, 2026
Organizer: Hospital Authority, Hong Kong
Contact: Research Assistant
Tel.: +85222555885
Email: js83213@hku.hk
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Is there a link between vitiligo and depression?
Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.